Floatz logo

Apg-5918

Epithelioid Sarcoma

Ascentage Pharma Group Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Epithelioid Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 1/2CCC
Tiragolumab
National Cancer Institute (NCI)
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Apg-5918 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
nasopharyngeal carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →